Breast cancer and breast enlargement can be equally nodular, but of course an experienced physician can distinguish most benign from malignant. Ultrasound and mammography can compensate for missed diagnoses and help the physician make a definitive diagnosis, and patients who still cannot be excluded may require enhanced MR, ultrasound or mammography-guided puncture biopsy so that the diagnosis can be confirmed in more than 95% of patients. If the tumor is malignant, the patient will be faced with the choice of the next treatment option. This is based on the biological characteristics of the tumor, clinical staging, and the patient’s personal wishes, which can be decided by breast-conserving surgery, preoperative neoadjuvant chemotherapy and endocrine therapy, modified radical surgery, simultaneous or second-stage breast reconstruction (which must be designed before surgery), genetic testing and the development of chemotherapy and radiotherapy programs based on this and combined with pathological results, and the assessment of whether targeted therapy, endocrine therapy and tumor immunotherapy values are needed. It can be said to be a systemic project that requires clear and definite thinking and guidance.